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Abstract 
Background: Immunological characterization of potential blood-stage malaria antigens would be a valuable strat-
egy in the development of an effective vaccine. Identifying B and CD4+ T cell epitopes will be important in under-
standing the nature of immune response. A previous study has shown that Plasmodium falciparum apical asparagine-
rich protein (PfAARP) stimulates immune response and induces potent invasion-inhibitory antibodies. Antibodies 
to PfAARP provide synergistic effects in inhibition of parasite invasion when used in combination with antibodies to 
other antigens. In the present study, an attempt was made to identify B cell and CD4+ T cell epitopes of PfAARP.
Methods: Balb/c mice were immunized with recombinant PfAARP and both cellular and humoral responses were 
analysed at various time points. Computerized databases [immune epitope database (IEDB) and B cell epitope predic-
tion (BCEPred)] were used to predict epitope sequences within PfAARP and predicted peptides were synthesized. 
In addition, nine 18 amino acid, long-overlapping peptides spanning the entire length of PfAARP were synthesized. 
Using these peptides, B cell and CD4+ T cell responses in PfAARP immunized mice were measured by ELISA and 
ELISPOT assays.
Results: Here, it is demonstrated that immunization of mice with PfAARP induced long-lasting, high-titre antibodies 
(4 months post immunization). Also, the recombinant protein was effective in inducing a pronounced Th1 type of 
immune response quantified by IFN-γ ELISA and ELISPOT. It was found that the predicted peptides did not represent 
the immunogenic regions of PfAARP. However, of the nine overlapping peptides, three peptides (peptides 3, 5 and 7) 
were strongly recognized by PfAARP-immunized sera and represented B cell epitopes. Also, peptide 3 elicited IFN- γ 
response, suggesting it to be a T-cell epitope.
Conclusions: Induction of long-lasting humoral and cellular response on PfAARP immunization in mice underscores 
its possible use as a blood-stage malaria vaccine candidate. Mapping of immunogenic regions may help in designing 
fusion chimera containing immunologically relevant regions of other vaccine target antigens and/or for multi-compo-
nent vaccine candidates.
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Background
In the search for an effective vaccine against Plasmodium 
falciparum, the deadliest form of malaria, a plethora of 
proteins from all parasite stages have been investigated 
over the past several decades. It is during the blood-stage 
of infection that malaria disease occurs and, therefore, 
special attention has been given to merozoite surface 
proteins and invasion ligands as targets for novel vaccines 
and therapeutics [1–3]. Blood-stage vaccines aim to con-
trol the severity of the disease and ultimately the clear-
ance of blood-stage parasites. This would prevent any 
symptoms of malaria and additionally block transmis-
sion [4]. A successful malaria vaccine will need to target a 
large population of antigenically diverse malaria parasites 
to protect people against the blood-stage infection [5, 6].
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Protective immunity to blood-stage malaria is elicited 
through complex interactions between both humoral and 
cell-mediated responses [7]. It is well established that B 
cells and antibodies play a crucial role in immunity to 
malaria. Naturally acquired immunity in individuals liv-
ing in malaria-endemic areas, which is slow to develop, is 
dependent largely on the acquisition of a repertoire of spe-
cific, protective antibodies directed against the blood-stage 
antigens [8]. Antibodies are associated with controlling 
levels of parasitaemia by directly inhibiting merozoite inva-
sion of erythrocytes or opsonizing merozoites for phago-
cytosis. In addition to the high-titre, long-lasting humoral 
response and memory response, development of an effec-
tive cellular response is equally important for an effective 
vaccine. The T cell response to an antigen is dependent on 
both the cytokine environment and antigen persistence 
during Plasmodium infection. Studies in both mice and 
humans have shown that pro-inflammatory cytokines, 
IFN-γ, TNF and IL-12, essentially mediate protective 
immunity to erythrocytic-stage malaria parasites [9]. Plas-
modium-specific interferon-gamma (IFN- γ) responses 
in vitro are associated with both human experimental and 
natural infections (reviewed in [10]). CD4+ T cells have 
been shown to control infection through IFN-γ production 
and provide help for the B-cell response required for con-
trol and elimination of infected red blood cells (RBCs) [11, 
12]. In general, IFN-γ from CD4+ T-cells has been shown 
to be important in maintaining strain-transcending blood-
stage immunity against Plasmodium chabaudi infection 
[13]. Similarly, in humans, IFN-γ contributes to a vast net-
work of protective responses against blood-stage parasite 
and correlated with better anti-parasite immunity [11, 14].
In addition to the type of immune response generated, 
determination of B and T cell epitopes in context of malaria 
vaccine development has been a useful exercise [15–18]. 
Identification of immunodominant regions may be helpful 
in the design of fusion chimera and/or for multi-component 
vaccine candidates [16]. Determination of short/specific 
regions may also present the advantage of large-scale pro-
duction of chimeric peptides, more stable than recombi-
nant proteins, comprising multiple malarial epitopes, at low 
cost. Advances in the in silico B and T epitope prediction 
databases have further assisted research interests towards 
epitope determination from potential vaccine candidates.
Plasmodium falciparum apical asparagine-rich protein 
(PfAARP) is a potential target antigen for inclusion into a 
malaria vaccine [19]. PfAARP is expressed in late schizont 
stage of the parasite and localized in the rhoptry neck [19]. 
Plasmodium falciparum apical asparagine-rich protein 
(PfAARP) contains an N-terminal signal sequence, aspara-
gine repeats, a conserved polyproline stretch and a C-ter-
minal transmembrane domain. A previous study showed 
that PfAARP ectodomain (amino acid 20–107) binds to 
human RBCs in neuraminidase and trypsin dependent 
manner [19]. Antibodies targeting PfAARP ectodomain 
(hereafter referred to as PfAARP) were effective in inhib-
iting parasite invasion in  vitro alone and also provided 
synergistic effects in parasite invasion inhibition in com-
bination with antibodies to other parasite proteins [19]. 
PfAARP was recognized by human serum samples from 
malaria-endemic regions pointing to its role in naturally 
acquired immunity [19]. In this study, PfAARP-specific 
humoral and cellular responses were analysed, and using 
a series of overlapping synthetic peptides, it was attempted 
to map the B and T cell epitopes of PfAARP in a murine 
model. Results in this study show that PfAARP induced 
high-titre, long-lived antibodies and robust cellular recall 
responses. Using a series of synthetic peptides, three B cell 
epitopes and one CD4+ T cell epitope of PfAARP were 
identified. These findings may provide rationale for design-
ing multiple epitope sub-unit vaccine based on PfAARP 
and other well-known malaria vaccine candidates.
Methods
Expression, purification and characterization 
of recombinant PfAARP
PfAARP (amino acid 20–107 with a C-terminal His 
tag) was cloned from the full length synthetic gene con- 
struct with 5′-CACATCATCAcatatgATTCTGCGTAAT 
AATAAAAGCC-3′ and 5′-TATATActcgagTCAGTGG 
T G G T G G T G G T G G T G AT C T T C AT T G T C T T 
CTTCATC-3′ as forward and reverse primers, respec-
tively, between NdeI and XhoI restriction sites. The 
recombinant plasmid was transformed in Escherichia coli 
BLR (DE3) cells and the transformed cells were grown in 
LB broth containing kanamycin (50 µg/ml) at 37 °C until 
it reached an optical density of 0.6–0.8 at 600 nm (OD600). 
The expression of the recombinant protein was induced 
by 1 mM isopropyl-β-d-thiogalactopyranoside (IPTG) for 
4 h and the expression level was analysed in un-induced 
and induced samples by SDS-PAGE and Western blotting.
For purification of the recombinant protein cell pellet 
from shake flask culture was homogenized in lysis buffer 
(20 mM NaH2PO4 pH 8.0, 300 mM NaCl, 5 mM benza-
midine-HCl, 10 mM imidazole and 100 µg/ml lysozyme) 
and lysed by sonication on ice for 20 min with a 9-s pulse 
on/off. The lysed culture was centrifuged and the result-
ing clear supernatant was loaded on to equilibrated Ni2+ 
charged, streamline-chelating resin for immobilized 
metal affinity chromatography (equilibration buffer: 
20  mM NaH2PO4 pH 8.0, 300  mM NaCl). The resin 
was subsequently washed with five column volumes of 
equilibration buffer. The bound protein was eluted with 
a step gradient of imidazole (10 to 500  mM) in 20  mM 
NaH2PO4 and 10 mM NaCl, pH 8.0. Eluted fractions were 
analysed by SDS-PAGE and protein-containing fractions 
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were pooled and loaded onto equilibrated Q-Sepharose 
column with equilibration buffer (20 mM NaH2PO4 and 
10  mM NaCl) for further purification. The protein was 
eluted with a step gradient of NaCl (10 to 500  mM) in 
20  mM NaH2PO4 pH 7.0. The eluates containing puri-
fied PfAARP were pooled and protein concentration was 
determined by bicinchoninic acid assay (BCA).
Homogeneity of the purified protein was assessed by SDS-
PAGE, by Western blot analysis with anti-His antibody and 
by reverse phase chromatography (RP-HPLC) on an analyti-
cal C18 column (Discovery Supelco). Endotoxin content of 
the purified protein was estimated by Limulus Amoebocyte 
Lysate (LAL) gel clot assay (Charles River Endosafe).
Immunization of mice with PfAARP formulated 
with Freund’s adjuvant
Balb/c mice were bred in the animal housing facility of 
International Centre for Genetic Engineering and Biotech-
nology (ICGEB) under pathogen-free conditions as per 
recommendation of the guide for the care and use of labora-
tory animals (ICGEB, India). ICGEB is licensed to conduct 
animal studies for research purposes under the registration 
number 18/1999/CPCSEA (dated 10/1/99). All the experi-
mental protocols were approved by the ICGEB Institutional 
Animal Care and Use Committee (IAEC: MAL).
For longevity study and B cell epitope mapping, a group 
of five mice (6–8  weeks old female mice) were immu-
nized subcutaneously in the hindfoot pads with 25 µg of 
PfAARP in complete Freund’s adjuvant and subsequently 
boosted with the same amount of protein in incomplete 
Freund’s adjuvant. Three booster doses were given on 
day 15, 30 and 65 post priming and sera was isolated on 
day 45, 60, 81, 102, 132, 162, and 192 post prime immu-
nization. Antibody titres were followed until day 192 viz 
4 months after the last booster immunization. In parallel, 
a group of five mice was immunized with PBS formulated 
with the adjuvant to serve as control mice.
For cellular response, phenotypic characterization and T 
cell epitope mapping, two groups of three mice each were 
immunized with 25 µg of the recombinant antigen in com-
plete Freund’s adjuvant and given a booster dose in incom-
plete Freund’s adjuvant with same amount of antigen on 
day 21 before harvesting spleen. Post-booster immuni-
zation, one group of mice was harvested on day 35 and 
another on day 42. Mice injected with adjuvant-formu-
lated PBS were used as the control group. Both the control 
and the test group mice were sacrificed on the same day 
and isolated splenic cells were analysed for T cell response.
Enzyme‑linked immunosorbent assay (ELISA)
Antibody responses in mice towards specific antigen 
and peptides were evaluated by ELISA. Briefly, 96-well 
micro-titre plates (Costar, Corning Inc.) were coated 
with recombinant PfAARP (200  ng per well) or peptides 
(800 ng per well) in 0.06 M carbonate–bicarbonate buffer 
(pH 9.6) and incubated overnight at 4 °C. Antigen-coated 
plates were washed three times with PBS-T (phosphate 
buffer saline-Tween 20) and blocked with 2  % skimmed 
milk in PBS (pH 7.2) for 2 h at 37 °C. Antigen-coated plates 
were sequentially incubated with serial dilutions of the 
immune sera from mice and then with HRP-conjugated 
(horse-radish peroxidase) rabbit anti-mouse second-
ary antibody in diluent (0.25  % skimmed milk in PBS-T) 
for 1 h each at 37 °C. The plates were washed with PBS-T 
and the enzyme reaction was developed by a mixture of 
o-phenylenediaminedihydrochloride (OPD) and hydrogen 
peroxide (H2O2) in citrate phosphate buffer (pH 5.0), the 
reaction was stopped by 2 N H2SO4 and OD was recorded 
at 492  nm by a Versamax ELISA reader (Molecular 
Devices). Cut-off values were determined as the mean plus 
twice the standard deviation (SD) for the pre-immuniza-
tion sera and were used to determine the endpoint titres.
For competitive ELISA, day 45 anti-PfAARP sera was 
pre-incubated with three different concentrations (25, 
50, 100 µg/ml) of PfAARP, peptide 1, peptide 3, peptide 
5 and peptide 7 for 30  min at room temperature (RT). 
Reactivity of these sera was tested against PfAARP by 
ELISA as per protocol described above.
Cell preparation
PfAARP-immunized mice were sacrificed at respective 
time points (day 35 and 42) and spleen was harvested. 
Spleens were dispersed into single cell suspensions by 
grinding using blunt ends of a 5-ml syringe and centri-
fuged to collect dispersed spleen cells. After centrifugation, 
erythrocyte lysis was performed by adding 1  ml of RBC 
lysis buffer [10 mM KHCO3, 155 mM NH4Cl and 0.1 mM 
EDTA (pH 7.4)] for 1 min and stopped with 9 ml of PBS. 
cells were centrifuged at 250×g for 10 min, resuspended in 
10 ml complete medium (RPMI 1640 supplemented with 
10  % FBS, 50  μg/ml gentamicin and 2  mM  l-glutamine) 
(cRPMI), passed through a 70-µm cell strainer to get single 
cell suspension and counted with haemocytometer.
Flow cytometry
Phenotypic characterization of B and CD4+ T cells in 
splenic cell population of PfAARP immunized mice 
was done by flow cytometry of total spleen cells. B cell 
characterization was done using B220, GL7, CD38 and 
IgG1 labelled antibodies and CD4+ T cells were charac-
terized using CD4, CD44, CD11a, and CD62L labelled 
antibodies. Briefly, spleen cells (1 ×  106 cells) from day 
42-sacrificed mice were stained with respective labelled 
antibodies (BD Biosciences). Cells were stained for 
30  min at 4  °C in the dark, washed twice with FACS 
buffer (PBS, 2  % FBS and 1  g/l sodium azide) and then 
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fixed with 1 % paraformaldehyde (PFA) in PBS for 30 min 
on ice. Stained cells were acquired with a FACS Calibur 
fluorescence-activated cell sorter (FACS) machine (BD 
Biosciences) and further analysed by FlowJo software 
(Tree Star). Profiles are presented as 5  % probability 
contours with outliers. Percent values with SD and fold 
change observed for PBS (control) and PfAARP (test) 
immunized mice were presented.
Cytokine response
Splenic cell cultures and cytokine assays were performed 
at the specified time points to measure secreted IFN-γ 
response. Splenic cells were resuspended in cRPMI and 
plated at 5  ×  105 cells/well in 96-well, flat-bottom plates 
(Costar, Corning Inc.). The spleen cells were stimulated 
in vitro at 37 °C in 5 % CO2 with PfAARP at 50 μg/ml or 
with the different peptides (both the predicted and overlap-
ping) (50 μg/ml) or with medium alone for 48 h. Concanav-
alin A (Con A) at a concentration of 1 μg/ml was used in all 
experiments as positive control. Supernatants were taken 
after 48 h of stimulation in culture and tested by sandwich 
ELISA for interferon gamma (IFN-γ) with BD-IFN-γ ELISA 
commercial kit as per manufacturer’s protocols.
IFN‑γ ELISPOT assay
IFN-γ ELISPOTs (BD Bioscience) were conducted 
according to the manufacturer’s instructions. Briefly, 
96-well ELISPOT plates (Millipore Multiscreen-HA) 
were coated with capture IFN-γ antibody (1:1000) over-
night at 4 °C to detect IFN-γ expressing cells. After three 
to five washes with sterile PBS, plates were blocked 
by cRPMI for 2  h at 37  °C. Spleen cells from PfAARP-
immunized mice were then added to the wells at 5 × 105 
cells per well in the presence of recombinant protein 
or respective peptides at concentration of 50  µg/ml, in 
final volume of 200  µl and incubated for 48  h at 37  °C 
in a 5  % CO2 incubator. A negative control containing 
5 × 105 cells per well without any peptide or protein and 
a positive control containing 5 × 105 cells per well in the 
presence of 1 µg/ml Con A were tested under the same 
conditions. After washing, plates were incubated with 
biotinylated anti-IFN-γ detection antibodies for 2  h at 
RT followed by streptavidin-HRP conjugate for 45 min at 
RT. After washing three times with PBS-T and once with 
PBS, 100  μl of soluble HRP substrate (3-amino-9-ethyl-
carbazole substrate in 0.05  M acetate buffer, pH 5.5) 
was added to each well and incubated at RT for 30 min 
and then the plates were rinsed with water. Wells were 
scanned and spots were counted by computer-assisted 
ELISPOT image analysis CTL Analyzer and software 
(CTL Analyzers). Images of individual wells of the ELIS-
POT plates were analysed for cytokine spots by compar-
ing wells containing antigen-stimulated immune cells 
and control wells with unstimulated immune cells. Cut-
off values were determined as the mean values plus twice 
the SD values obtained for control wells with unstimu-
lated cells. Thus, values which were greater than the cut-
off values were treated as positive ELISPOT responses.
Prediction of B and T cell epitopes in AARP
B and T cell epitopes were predicted in mouse using bio-
informatic databases. The databases used to predict B 
cell epitopes were immune epitope data base (IEDB) and 
B-cell epitope prediction (BCEPred). The prediction tools 
used in IEDB were Chou and Fasman beta turn predic-
tion, Parker hydrophilicity prediction and Bepipred linear 
epitope prediction [20] whereas in BCEPred hydrophilic-
ity, flexibility, accessibility, turns, exposed surface, polar-
ity, and antigenic propensity were simultaneously used 
for prediction [21].
Fifteen amino acid, long helper T cell epitopes were 
predicted from IEDB for H2-IAb, H2-IAd and H2-IEd 
alleles of the mouse locus H2-I with ‘IEDB recommended 
prediction method’ using the Consensus approach [22]. 
An alternate prediction method in IEDB ‘SMM-align’ 
was also used to predict the direct MHC binding affinity 
of the peptides for the three alleles of H2-I locus.
Peptide synthesis
The two predicted peptide sequences, Peptide A (32P I S K 
T N E EEE G K I N I N47) and Peptide B (92E S D N D E E 
E E E D E E D N E D L107) from PfAARP were synthesized 
by standard, solid-phase synthetic methods [23]. Briefly, 
peptides were synthesized on Wang Resin (0.44  mmol/g) 
using Fmoc methodology at 0.3 mM scale. Couplings were 
performed by using N,N-diisopropylcarbodiimide and Fmoc 
deprotection was performed with 20 % piperidine in dimeth-
ylformamide. After addition of the final residue, the resin was 
rinsed with dimethylformamide/dichloromethane/methanol 
and dried. The final peptide de-protection and cleavage from 
the resin was achieved with 20 ml of trifluoroacetic acid/phe-
nol/water/triisopropylsilane (17.6:1:1:0.4) for 2 h. The crude 
peptide was precipitated with cold ether, filtered, lyophilized, 
and stored at −20 °C as dry powder. Peptide purity was con-
firmed by RP-HPLC using water acetonitrile gradient on a 
C-18 column (Discovery Supelco).
Eighteen amino acid long nine overlapping peptides 
spanning PfAARP were commercially synthesized by 
standard solid phase synthesis methods (GenicBio Lim-
ited, China).
Statistical analysis
Statistical analyses were performed using both Excel 
(Microsoft Office) and GraphPad Prism statistical soft-
ware (GraphPad Software Inc.). Data are expressed as the 
mean ± SD when derived from three or more values. To 
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determine the level of significance, a Student t test was 
performed and a p < 0.05 was considered significant.
Results
Purification and characterization of PfAARP
PfAARP described in this study comprises amino acid 
20–107, devoid of signal sequence, asparagine repeats, 
polyproline stretch, and transmembrane domain of the 
protein (Fig. 1a). PfAARP was expressed as a soluble pro-
tein in cytosolic fractions and purified to homogeneity 
by a three-step chromatographic procedure, including 
immobilized metal affinity chromatography followed by 
anion exchange chromatography and finally RP-HPLC, 
to remove endotoxin from the purified protein. Puri-
fied PfAARP showed an apparent mobility at ~17  kDa 
on SDS-PAGE instead of its predicted molecular mass 
of 11.6  kDa (Fig.  1b). This discrepancy in mobility of 
the recombinant protein may be due to highly acidic pI 
(5.06) of the protein and the unusual amino acid compo-
sition. Such aberrant migration on SDS-PAGE has been 
observed with a number of other malaria proteins, such 
as RESA and also for Toxoplasma proteins (another Api-
complexan parasite) [24, 25]. Identity of the recombinant 
protein was confirmed by Western blot analysis under 
reducing conditions with anti-His monoclonal antibody 
(Fig.  1c). The results from both SDS-PAGE analysis and 
RP-HPLC showed that the purity of the recombinant pro-
tein was greater than 95 % (Fig. 1d). Gel clot assay based 
on LAL reagent kit showed that endotoxin level of the IEX 
purified fraction was high (~5000 EU per 25 µg protein) 
which was significantly reduced to ~2.5 EU per 25 µg of 
the protein on RP-HPLC of IEX fractions. This endo-
toxin level is well below the permissible limit (30 EU per 
25 µg protein) for bacterially expressed proteins used for 
immunization studies in small animals. Application of RP-
HPLC for endotoxin removal from bacterially expressed 
proteins has been used previously for other proteins, such 
as human cryptic plasminogen-derived domain Kringle 5 
[26]. Purified PfAARP with low, acceptable level of endo-
toxin content was used for immunization in mice.
Humoral responses generated to PfAARP
To study immunogenicity of PfAARP, a group of five 
mice were immunized and boosted with protein formu-
lated with Freund’s adjuvant, and serum was isolated at 
different time points as described in the immunization 
Fig. 1 Purification and characterization of PfAARP. a Position of PfAARP ectodomain in the protein sequence. b Mobility of recombinant purified 
protein on SDS-PAGE. c Western blot of recombinant purified protein with anti-His monoclonal antibody. d RP-HPLC profile of purified protein 
showing the purity of the protein
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schedule (Fig.  2a). The kinetics of humoral response by 
ELISA showed that high-titre antibodies (of the order of 
106) were raised upon PfAARP immunization and the 
response persisted until day 192, showing that PfAARP-
specific antibodies stayed in circulation even 4  months 
after the last booster dose (Fig.  2b). Since the half-life 
of secreted IgGs is not more than 21  days, it may be 
inferred from these results, that longevity of the observed 
antibody response may be the result of both long-lived 
plasma cells (LLPCs) and/or memory B cells (MBCs) 
[27]. As expected, the control mice did not show any 
antigen-specific antibody response to PfAARP (Fig. 2b).
In order to understand the phenotypic and functional 
changes involved in generation of long-lived humoral 
response, changes in surface markers of mice splenic 
B cells induced by PfAARP immunization were ana-
lysed (Table  1). Flow cytometric results showed a ~1.4-
fold up-regulation in the expression of CD38 on B220+ 
splenic cells in protein-immunized mice as compared 
to PBS-immunized mice. This increase in CD38 expres-
sion indicated B cell activation and isotype switching of 
immunoglobulins. Isotype switching in splenic cells of 
PfAARP-immunized mice was further confirmed by a 
~1.8-fold increase in expression of IgG1 on B220+ splenic 
cells. This increase in isotype switching and IgG1+ cells 
correlated well with PfAARP-specific high antibody titres 
observed in the serum. In addition to B cell activation 
and isotype switching, immunization with PfAARP also 
induced germinal centre (GC) formation as observed by 
a ~2.5 increase in B220+ GL7+ cells in spleen, the site for 
generation of MBCs. GC formation in spleen of protein 
Fig. 2 Humoral response generated to PfAARP. a Immunization schedule stating prime, booster doses and bleed of mice for humoral response. b 
Kinetics of humoral response generated to the protein in terms of endpoint titres
Table 1 Phenotypic characterization of  splenic CD4+ T 
cells and B cell in PfAARP and PBS immunized mice
Spleen cells from recombinant protein (test) and PBS (control) immunized mice 
were stained with respective labelled antibodies, acquired by FACS Calibur and 
analysed by FlowJo. Percent values with standard deviation and the fold change 
observed for the control and test mice are presented




B220+GL7+ 0.34 ± 0.05 0.89 ± 0.49 2.50
B220+CD38+ 24.5 ± 3.53 33.95 ± 7.70 1.38
B220+CD27+ 0.6 ± 0.45 3.40 ± 2.18 5.67
B220+IgG1+ 0.31 ± 0.13 0.55 ± 0.09 1.80
CD4+CD44+ 22.35 ± 2.89 25.8 ± 0.84 1.15
CD4+CD11a+ 9.68 ± 2.85 18.05 ± 1.9 1.86
CD4+CD62L+ 28.45 ± 11.8 16.9 ± 0.56 0.59
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immunized mice was further supported by ~five-fold 
increase in the expression of CD27 on B220+ splenic B 
cells. An increase in CD27 on B cells promoted the for-
mation of GC and consequent IgG production [28]. 
Together, these results clearly indicated that upon AARP 
immunization, there was an early and persistent B cell 
activation, induction of GC formation, as well as IgG+ 
MBC generation.
Cellular response generated to PfAARP
To analyse cell-mediated immune (CMI) responses, 
spleen cells were harvested from immunized mice 
(PfAARP immunized) and control mice (PBS immu-
nized) at different time points and cultured in medium 
alone or stimulated with PfAARP. CMI responses 
induced by PfAARP were kinetically analysed by IFN-
γ-ELISA and ELISPOT. Spleen cells from control mice 
stimulated with AARP produced insignificant level 
of IFN-γ throughout the course of the experiment 
(~57.4 pg/ml for day 42) (Fig. 3a). On the other hand, as 
expected, spleen cells from PfAARP-immunized mice 
produced high IFN-γ (~738  pg/ml) on day 35 and the 
level increased markedly by day 42 (~1804  pg/ml) post 
prime immunization (p  <  0.05) (Fig.  3a). This increase 
in secreted IFN- γ levels in splenic cells from protein-
immunized mice stimulated with PfAARP may be due to 
the formation of antigen specific Th1 cells upon protein 
immunization. Results from ELISPOT assay also showed 
a significant number of IFN-γ-producing Th1 cells in 
PfAARP-immunized mice as compared to PBS-immu-
nized mice [~1.5 (day 0) vs ~15.5 (day 35) and ~29.677 
(day 42)] (Fig. 3b). Con A was used as a positive control 
for both IFN-γ ELISA and ELISPOT assays. Figure  3c 
showed representative images of ELISPOT wells stimu-
lated with Con A, PfAARP and media. These results, 
therefore, indicated that an effective cellular, particu-
larly, IFN-γ response, was generated during PfAARP 
immunization. IFN-γ has been shown to be a critical 
cytokine produced during malaria infection that con-
trols parasite growth, probably by splenic macrophage 
activation to phagocytose-parasitized RBCs [10]. Stud-
ies have also shown that there may exist a correlation of 
pRBC (extracellular merozoites and intra-erythrocytic 
parasites) specific IFN-γ to protection (reviewed in [11]).
Fig. 3 Cellular response generated to PfAARP. a Secretion of IFN-γ by splenic cells and b Number of IFN-γ secreting cells when splenic cells from 
mice immunized with either PfAARP or PBS were stimulated with protein or media (negative control) at different time points. Con A was used as 
positive control. c Representative images of ELISPOT wells stimulated with Con A, PfAARP and media
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To analyse the cell surface expression of activation 
markers in PfAARP- and PBS-immunized mice, cells 
were stained with anti-CD4, -CD44 and -CD11a, mark-
ers which increase on activation of T cells, and -CD62L, 
a molecule with a decreased cell surface expression on T 
cell activation (Table 1). Flow cytometric results showed 
~1.15-fold and ~1.86-fold up-regulation in CD44 and 
CD11a expression, respectively, on gated CD4+ T cells 
in AARP-immunized mice compared to PBS-immunized 
mice. Also, there was a significant reduction (~0.59-fold 
change) in the expression of CD62L on gated CD4+ T 
cells in PfAARP-immunized mice. These results clearly 
indicated that following immunization, PfAARP induced 
an activated phenotype on CD4+ T cells and a strong 
Th1 response. Also, it has been shown that cognate T cell 
responses significantly contribute to the generation of 
potentially effective antibody response in both infection-
induced and vaccine-induced immunity against malaria 
[29]. Strong T cell response induced by PfAARP is in 
quite contrast to a number of crucial parasite antigens, 
such as PfMSP-119 that show weak T cell recognition, 
which compromises their efficacies as vaccine candidates 
[30].
Prediction of epitopes, peptide synthesis 
and immunogenicity testing of predicted epitopes
Since a robust humoral and cellular immune response 
is generated in mice immunized with PfAARP, it was 
next attempted to determine linear minimal immuno-
genic regions of the protein. Two B cell epitopes (10–15 
residues) were predicted by BCEPred and one epitope 
(16 residues) by IEBD (Fig.  4a). Also, ten helper T cell 
epitopes (15 residues) were predicted by IEDB-rec-
ommended prediction method and four helper T cell 
epitopes by SMM-align method to the three alleles of 
H-2I MHC locus of mice (Fig. 4a). Peptides predicted as 
B and T cell epitopes mainly overlapped in two fragments 
of PfAARP, of which one was localized in the centre and 
other in C-terminus of the protein. Therefore, two pep-
tides corresponding to residue 32–47 and 92–107 were 
synthesized (Peptide A and B) by standard solid phase 
methods [23]. Peptide purity was analysed by RP-HPLC 
and was shown to be >90 % (Fig. 4b).
PfAARP-immunized mice sera were tested against Pep-
tides A and B by ELISA to determine whether they rep-
resented B cell epitopes. While, immune sera at 1:500 
dilution showed high reactivity to the protein (OD492 
Fig. 4 Epitope prediction and peptide synthesis. a B and T cell epitopes were predicted by IEDB and BCEPred. b Selected peptides were synthe-
sized using Fmoc methodology and their purity was determined by RP-HPLC
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~2.5), there was no reactivity with Peptide A (OD492 
~0.05) or B (OD492 ~0.08) (Fig.  5a). These results sug-
gested that the predicted peptides in fact do not repre-
sent B cell epitopes. As expected, pre-immune sera did 
not show reactivity with PfAARP or Peptide A and B.
Peptides A and B were also analysed in a cellular 
response assay to determine whether these represented 
putative CD4+ T cell epitopes. Following in vitro stimula-
tion of splenic cells from PfAARP-immunized mice with 
the recombinant protein, splenic cells produced signifi-
cantly higher levels of IFN-γ (~1800  pg/ml) when com-
pared to control mice (~57  pg/ml) (Fig.  5b). However, 
both Peptide A and B failed to stimulate IFN-γ produc-
tion (~50 pg/ml) in splenic cells and thus do not repre-
sent CD4+ T cell epitopes. These results were somewhat 
surprising but at the same time clearly indicated that 
predicted peptides may not always turn out to be actual 
immunodominant epitopes. Experimental validation of 
computationally predicted epitopes for CelTOS, a pro-
tein expressed in motile stages of malaria parasite, indi-
cated the limited accuracy of prediction algorithms [31]. 
A recent study with three novel viral-vectored antigens 
(PfUIS3, PfLSA1 and PfLSAP2) also supported that, of 
the large number of predicted epitopes only a few could 
be validated experimentally [32].
Evaluation of overlapping peptides as B and T cell epitopes
Since predicted peptide sequences did not turn out to be 
immunodominant epitopes of PfAARP, a series of over-
lapping peptides covering the whole sequence of PfAARP 
was synthesized. These nine peptides, each 18 residues 
long with an overlap of nine amino acids (Fig.  6), were 
obtained from a commercial source (GenicBio Ltd).
Peptides 1–9 were evaluated for their reactivity with 
antisera from PfAARP-immunized mice by ELISA. Reac-
tivity of day-45 sera at a dilution of 1:1000 with PfAARP 
(OD492 ~2.1) was used as the positive control and the 
pre-immune sera (OD492 ~0.1) was used as negative con-
trol. ELISA results showed that PfAARP antisera reacted 
with peptides 3, 5, 6 and 7 (Fig. 7a); significant reactivity 
was seen with peptide 7 (OD492 ~1.2) followed by moder-
ate reactivity with peptide 3 (OD492 ~0.8) and peptide 5 
(OD492 ~0.6) and low but positive response to peptide 6 
(OD492 ~0.4), other peptides did not show reactivity with 
the antisera. ELISA of serially diluted immune sera with 
these peptides showed that the endpoint titres were in 
the range of 105 as against the 106 towards PfAARP. The 
kinetics of immune response to PfAARP with regard to 
peptides 3, 5 and 7 showed a peak at day 45 and another 
at day 102 whereas for peptide 6, the antibody response 
peaked only once at day 45 (Fig.  7b). Thus, the kinetics 
of anti-PfAARP sera towards peptides is similar to that 
observed with the recombinant protein.
To further investigate the specificity of anti-PfAARP 
sera binding to peptides 3, 5 and 7, a competitive ELISA 
was performed as described previously. Anti-PfAARP 
serum was pre-incubated with different concentrations 
(25, 50 and 100  µg/ml) of PfAARP, peptide 1, peptide 
3, peptide 5, and peptide 7, and then these sera were 
assessed for their reactivity to PfAARP. ELISA results 
clearly showed that on pre-incubation with PfAARP, 
reactivity of anti-PfAARP sera to the recombinant pro-
tein decreased in a concentration-dependent manner 
Fig. 5 Evaluation of peptides A and B as epitopes. a ELISA was per-
formed for the two peptides with protein-immunized sera to evaluate 
as B cell epitopes; ELISA with recombinant antigen and with pre-
immune sera was used as positive and negative controls, respectively. 
b Splenic cells from protein immunized mice were stimulated with 
peptides and IFN-γ secretion in the culture supernatant was analysed 
by ELISA to evaluate T cell epitopes; stimulation with protein and 
media were used as positive and negative control
Page 10 of 14Kalra et al. Malar J  (2016) 15:457 
with ~95 % reduction at 100 µg/ml PfAARP (Fig. 7c). The 
reactivity of anti-PfAARP sera to PfAARP also decreased 
significantly on pre-incubation with synthetic peptides 
in a concentration-dependent manner with maximum 
reduction observed on pre-incubation with peptide 7 
(~80  % reduction at 100  µg/ml) followed by peptide 5 
(~60  % reduction at 100  µg/ml) and peptide 3 (~40  % 
reduction at 100 µg/ml) (Fig. 7c). However, there was no 
reduction in reactivity of PfAARP antisera when incu-
bated with peptide 1, a peptide which did not react to 
PfAARP antisera suggesting that reactivity of peptides 3, 
5 and 7 to anti-PfAARP sera is specific. These results sug-
gested that peptides 3, 5 and 7 represented B cell epitopes 
of PfAARP with peptide 7 being the dominant one.
The nine overlapping peptides were also tested for 
the presence of T cell epitopes by IFN-γ based cellu-
lar response assay. Spleen cells from AARP-immunized 
mice were stimulated with nine overlapping peptides and 
change in IFN-γ level or number of IFN-γ-producing Th1 
cells was determined by ELISA and ELISPOT, respec-
tively. Out of the nine peptides, only peptide 3 was able 
to induce IFN-γ secretion in the culture supernatant. 
At day 35 following primary immunization, peptide 3 
induced IFN-γ levels to ~200  pg/ml and by day 42 the 
level increased to ~535  pg/ml compared to ~57  pg/ml 
by splenic cells of PBS immunized mice (Fig. 8a). Splenic 
cells from day 35 and day 42 mice were stimulated with 
different peptides for 48  h to determine the numbers 
of IFN-γ-secreting cells. As observed from ELISPOT 
results, peptide 3 induced the significant proportion of 
IFN-γ-secreting cells ~30.166 (day 42) and ~5.82 (day 35) 
as against ~1.5 in the control group mice. No significant 
reactivity was observed with other peptides (Fig.  8b). 
These results indicated that peptide 3 represented T cell 
immunodominant epitope, found at amino acids #38–55 
of PfAARP, although the computational methods were 
not able to predict this sequence as a putative B and/or T 
cell epitope.
Epitope mapping of crucial antigens has been a use-
ful exercise that has been done using multiple methods, 
including monoclonal antibodies, X-ray crystallography 
and Nuclear magnetic resonance techniques [33–36]. 
Fig. 6 Overlapping peptides of PfAARP. Eighteen amino acid overlapping peptides were synthesized where each next peptide overlaps previous 
peptide by nine amino acids
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For example, a peptide was identified from PfRH5 by 
virus-like particle (VLP) approach and a mAb to the 
peptide completely inhibited parasite invasion in  vitro 
[17]. A synthetic peptide representing circularized struc-
ture of five NANP repeats of circumsporozoite protein 
(CSP) was developed depending on the crystal structure 
of CSP repeat region [37]. Although these methods are 
extremely reliable, they tend to be resource intensive, 
time consuming and have rather low throughput for fine 
epitope mapping. In contrast, overlapping peptides, in 
combination with computational methods are low cost, 
efficient, and can be rationally employed to identify linear 
Fig. 7 Evaluation of overlapping peptides as B cell epitopes. a ELISA was performed for the nine overlapping peptides with protein-immunized 
sera at a dilution of 1:1000. Reactivity of recombinant protein and pre-immune sera was used as positive and negative control, respectively. b Kinet-
ics of the sera to peptides 3, 5, 6, and 7 with respect to recombinant protein. c ELISA of PfAARP antisera pre-incubated with different concentrations 
(25, 50 and 100 µg/ml) of PfAARP, peptide 1, peptide 3, peptide 5 and peptide 7 to PfAARP at a dilution of 1:1000. Reactivity of pre-immune sera and 
immune sera without pre-incubation was used as controls. White bar indicates the reactivity of day 45 anti-PfAARP sera with PfAARP
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B cell epitopes [15, 18, 38–40]. This approach has been 
used extensively to identify epitopes of some crucial par-
asite antigens, such as AMA-1, SERA-5, MSP-2, MSP-9, 
and the selected peptides have been analysed as potential 
vaccine candidates alone and in combination with pep-
tides to other antigens [15, 38, 39, 41].
Conclusion
The fine specificity of immune response generated to 
PfAARP, a P. falciparum potential blood-stage vaccine can-
didate was analysed in a murine model. Immunization with 
PfAARP induced a high-titre, long-lived antibody response 
which stayed in circulation for more than 4  months post 
immunization. Also, the recombinant protein was effective 
in inducing a pronounced Th1 type of immune response 
quantified by IFN-γ ELISA and ELISPOT. On immuniza-
tion, PfAARP induced activation of B and CD4+ T cells, 
immunoglobulin isotype switching and formation of GC in 
splenic cell population. It was also found that the predicted 
epitopes in fact did not represent B and T cell epitopes of 
PfAARP. However, one T cell and three B cell epitopes of 
PfAARP were mapped by analysing overlapping peptides 
spanning the complete protein, the efficacy of which could 
be further evaluated to be a component of sub-unit vac-
cines. These results support the further evaluation of this 
vaccine candidate in a challenge model.
Abbreviations
BCA: bicinchoninic acid assay; BCEPred: B cell epitope prediction; CMI: cell-
mediated immune; Con A: concanavalin A; cRPMI: complete RPMI; CSP: cir-
cumsporozoite protein; ELISA: enzyme linked immuno sorbent assay; ELISPOT: 
enzyme linked immunospot assay; FACS: fluorescence-activated cell sorter; 
GC: germinal centre; HRP: horse-radish peroxidase; H2O2: hydrogen peroxide; 
ICGEB: International Centre for Genetic Engineering and Biotechnology; IEDB: 
immune epitope database; IFN-γ: interferon-gamma; IPTG: isopropyl-β-d-
thiogalactopyranoside; LAL: limulus amoebocyte lysate; LLPC: long-lasting 
plasma cells; MBC: memory B cells; OD: optical density; OPD: o-phenylene-
diaminedihydrochloride; PBS: phosphate buffer saline; PfAARP: Plasmodium 
falciparum apical asparagine-rich protein; PFA: paraformaldehyde; RBC: red 
blood cells; RP-HPLC: reverse-phase high performance liquid chromatography; 
RT: room temperature; SD: standard deviation; VLP: virus-like particle.
Fig. 8 Evaluation of overlapping peptides as T cell epitopes. Assessment of IFN-γ response either released (a) or number of IFN-γ secreting Th1 cells 
(b) on stimulation of protein-immunized splenic cells with protein, peptides and media. Splenic cells from PBS-immunized mice (D 0) were used as 
negative (adjuvant) control
Page 13 of 14Kalra et al. Malar J  (2016) 15:457 
Authors’ contributions
VSC, PM and AK designed the research; AK performed the research; VSC con-
tributed reagents/analytic tools; VSC, PM and AK analysed data; VSC, PM and 
AK wrote the paper. All authors read and approved the final manuscript.
Acknowledgements
We are thankful to Dr. Jyotheeswara Reddy Edula for cloning of PfAARP gene. 
We also thank Dr. Deepak Gaur for his helpful discussions. We thank Ashok Das 
and Rakesh Singh for assistance in handling animals at animal house.
Competing interests
The authors declare that they have no competing interests.
Availability of data and materials
The authors declare that all data generated or analysed during this study are 
included in this published article.
Ethics approval and consent to participate
ICGEB is licensed to conduct animal studies for research purposes under the 
registration number 18/1999/CPCSEA (dated 10/1/99). All the experimental 
protocols were approved by the ICGEB Institutional Animal Care and Use 
Committee (IAEC: MAL).
Funding
We acknowledge ICGEB core grant and Program Support Grant (CEIB), DBT 
for funding the research work. We also acknowledge Council of Scientific and 
Industrial Research (CSIR) for providing senior research fellowship to AK.
Received: 18 June 2016   Accepted: 30 August 2016
References
 1. Beeson JG, Drew DR, Boyle MJ, Feng G, Fowkes FJI, Richards JS. Merozoite 
surface proteins in red blood cell invasion, immunity and vaccines 
against malaria. FEMS Microbiol Rev. 2016;40:343–72.
 2. Hoffman SL, Vekemans J, Richie TL, Duffy PE. The march toward malaria 
vaccines. Am J Prev Med. 2015;49:S319–33.
 3. Halbroth BR, Draper SJ. Recent developments in malaria vaccinology. Adv 
Parasitol. 2015;88:1–49.
 4. Goodman AL, Draper SJ. Blood-stage malaria vaccines—recent progress 
and future challenges. Ann Trop Med Parasitol. 2010;104:189–211.
 5. Birkett AJ, Moorthy VS, Loucq C, Chitnis CE, Kaslow DC. Malaria vaccine 
R&D in the decade of vaccines: breakthroughs, challenges and opportu-
nities. Vaccine. 2013;31:233–43.
 6. Ogutu BR, Apollo OJ, McKinney D, Okoth W, Siangla J, Dubovsky F, et al. 
Blood stage malaria vaccine eliciting high antigen-specific antibody con-
centrations confers no protection to young children in Western Kenya. 
PLoS ONE. 2009;4(3):4708.
 7. Beeson JG, Osier FH, Engwerda CR. Recent insights into humoral and cel-
lular immune responses against malaria. Trends Parasitol. 2008;24:578–84.
 8. Baird JK. Host age as a determinant of naturally acquired immunity to 
Plasmodium falciparum. Parasitol Today. 1995;11:105–11.
 9. Malaguarnera L, Musumeci S. The immune response to Plasmodium 
falciparum malaria. Lancet Infect Dis. 2002;2:472–8.
 10. Stanisic DI, Good MF. Examining cellular immune responses to 
inform development of a blood-stage malaria vaccine. Parasitology. 
2016;143:208–23.
 11. McCall MBB, Sauerwein RW. Interferon-γ–central mediator of protec-
tive immune responses against the pre-erythrocytic and blood stage of 
malaria. J Leukoc Biol. 2010;88:1131–43.
 12. Stephens R, Langhorne J. Effector memory Th1 CD4 T cells are 
maintained in a mouse model of chronic malaria. PLoS Pathog. 
2010;6:e1001208.
 13. da Silva HB, de Salles EM, Panatieri RH, Boscardin SB, Rodríguez-Málaga 
M, Álvarez JM, et al. IFN-γ—induced priming maintains long-term 
strain-transcending immunity against blood-stage Plasmodium chabaudi 
malaria. J Immunol. 2013;191:5160–9.
 14. McCall MB, Hopman J, Daou M, Maiga B, Dara V, Ploemen I, et al. Early 
interferon-gamma response against Plasmodium falciparum correlates 
with interethnic differences in susceptibility to parasitemia between 
sympatric Fulani and Dogon in Mali. J Infect Dis. 2010;201:142–52.
 15. Bueno LL, Lobo FP, Morais CG, Mourao LC, De Avila RA, Soares IS, 
et al. Identification of a highly antigenic linear B cell epitope within 
Plasmodium vivax apical membrane antigen 1 (AMA-1). PLoS ONE. 
2011;6:e21289.
 16. Cech PG, Aebi T, Abdallah MS, Mpina M, Machunda EB, Westerfeld N, et al. 
Virosome-formulated Plasmodium falciparum AMA-1 and CSP derived 
peptides as malaria vaccine: randomized phase 1b trial in semi-immune 
adults and children. PLoS ONE. 2011;6:e22273.
 17. Ord RL, Caldeira JC, Rodriguez M, Noe A, Chackerian B, Peabody DS, et al. 
A malaria vaccine candidate based on an epitope of the Plasmodium 
falciparum RH5 protein. Malar J. 2014;13:326.
 18. Armistead JS, Morlais I, Mathias DK, Jardim JG, Joy J, Fridman A, et al. 
Antibodies to a single, conserved epitope in Anopheles APN1 inhibit 
universal transmission of Plasmodium falciparum and Plasmodium vivax 
malaria. Infect Immun. 2014;82:818–29.
 19. Wickramarachchi T, Devi YS, Mohmmed A, Chauhan VS. Identifica-
tion and characterization of a novel Plasmodium falciparum merozoite 
apical protein involved in erythrocyte binding and invasion. PLoS ONE. 
2008;3:e1732.
 20. Immune epitope database. http://www.tools.iedb.org/bcell/.
 21. B cell epitope prediction. http://www.imtech.res.in/raghava/bcepred/
bcepred_submission.html.
 22. Immune epitope database. http://www.tools.iedb.org/mhcii/.
 23. Merrifield RB. Solid phase peptide synthesis. I. The synthesis of a tetrapep-
tide. J Am Chem Soc. 1963;85:2149–54.
 24. Favaloro JM, Coppel RL, Corcoran LM, Foote SJ, Brown GV, Anders RF, 
Kemp DJ. Structure of the RESA gene of Plasmodium falciparum. Nucl 
Acids Res. 1986;14:8265–77.
 25. Ossorio PN, Schwartzman JD, Boothroyd JC. A Toxoplasma gondii rhoptry 
protein associated with host cell penetration has unusual charge asym-
metry. Mol Biochem Parasitol. 1992;50:1–15.
 26. Dudley A, McKinstry W, Thomas D, Best J, Jenkins A. Removal of 
endotoxin by reverse phase HPLC abolishes anti-endothelial cell 
activity of bacterially expressed plasminogen kringle 5. Biotechniques. 
2003;35:724–32.
 27. Stanisic DI, Barry AE, Good MF. Escaping the immune system: how the 
malaria parasite makes vaccine development a challenge. Trends Parasi-
tol. 2013;29:612–22.
 28. Xiao Y, Hendriks J, Langerak P, Jacobs H, Borst J. CD27 is acquired by 
primed B cells at the centroblast stage and promotes germinal center 
formation. J Immunol. 2004;172:7432–41.
 29. Walker KM, Okitsu S, Porter DW, Duncan C, Amacker M, Pluschke G, et al. 
Antibody and T-cell responses associated with experimental human 
malaria infection or vaccination show limited relationships. Immunology. 
2015;145:71–81.
 30. Alaro JR, Angov E, Lopez AM, Zhou H, Long CA, Burns JM. Evaluation of 
the immunogenicity and vaccine potential of recombinant Plasmodium 
falciparum merozoite surface protein 8. Infect Immun. 2012;80:2473–84.
 31. Bergmann-Leitner ES, Chaudhury S, Steers NJ, Sabato M, Delvecchio 
V, Wallqvist AS, et al. Computational and experimental validation of B 
and T-cell epitopes of the in vivo immune response to a novel malarial 
antigen. PLoS ONE. 2013;8:e71610.
 32. Longley RJ, Halbroth BR, Ewer KJ, Hill AVS, Spencer AJ. Identification of 
immunodominant responses to the Plasmodium falciparum antigens 
PfUIS3, PfLSA1 and PfLSAP2 in multiple strains of mice. PLoS ONE. 
2015;10:e0144515.
 33. Bhatti AR, Micusan VV. Production and characterization of anti-peptide 
monoclonal antibodies with specificity for Staphylococcal enterotoxins A 
and B. J Microbiol Methods. 1999;35:143–9.
 34. Irving MB, Pan O, Scott JK. Random-peptide libraries and antigen-
fragment libraries for epitope mapping and the development of vaccines 
and diagnostics. Curr Opin Chem Biol. 2001;5:314–24.
 35. Rux J. Type-specific epitope locations revealed by X-ray crystallographic 
study of Adenovirus type 5 hexon. Mol Ther. 2000;1:18–30.
 36. Mayer M, Meyer B. Group epitope mapping by saturation transfer dif-
ference NMR to identify segments of a ligand in direct contact with a 
protein receptor. J Am Chem Soc. 2001;123:6108–17.
Page 14 of 14Kalra et al. Malar J  (2016) 15:457 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
 37. Ghasparian A, Moehle K, Linden A, Robinson JA. Crystal structure of an 
NPNA-repeat motif from the circumsporozoite protein of the malaria 
parasite Plasmodium falciparum. Chem Commun (Camb). 2006;3:174–6.
 38. Sharma P, Kumar A, Singh B, Bharadwaj A, Sailaja VN, Adak T, et al. Charac-
terization of protective epitopes in a highly conserved Plasmodium falci-
parum antigenic protein containing repeats of acidic and basic residues. 
Infect Immun. 1998;66:2895–904.
 39. Yagi M, Bang G, Tougan T, Palacpac NMQ, Arisue N, Aoshi T, et al. Protec-
tive epitopes of the Plasmodium falciparum SERA5 malaria vaccine reside 
in intrinsically unstructured N-terminal repetitive sequences. PLoS ONE. 
2014;9:e98460.
 40. Mueller MS, Renard A, Boato F, Vogel D, Naegeli M, Zurbriggen R, et al. 
Induction of parasite growth-inhibitory antibodies by a virosomal 
formulation of a peptidomimetic of loop I from domain III of Plasmodium 
falciparum apical membrane antigen 1. Infect Immun. 2003;71:4749–58.
 41. Balam S, Olugbile S, Servis C, Diakité M, D’Alessandro A, Frank G, et al. 
Plasmodium falciparum merozoite surface protein 2: epitope mapping 
and fine specificity of human antibody response against non-polymor-
phic domains. Malar J. 2014;13:510.
